Your search for non small cell lung cancer returned 132 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove
Older than 2 years remove

Your search for non small cell lung cancer returned 132 results

Sort Results:

Relevant Recent

Durvalumab Extends Survival vs Placebo in Stage 3 Non-Small Cell Lung CA

Overall survival was significantly prolonged with durvalumab versus placebo (stratified hazard ratio [HR] for death, 0.68; P=.0025). For progression-free survival, the median duration was 17.2 months in the durvalumab group and 5.6 months in the placebo group.
ACR/ARHP 2018 Annual Meeting

Biologic DMARD Treatment Linked to Weight Gain in Inflammatory Arthritis

Small but significant increases in weight (0.02lb) and BMI (0.006 lbl P<.001 for both) were observed over time. Moreover, a negative association between DAS28 and increased weight (-0.56) as well as BMI (-0.08; P<.001 for both) was reported, implying that an increase in weight was linked to lower disease activity.

Survival Time Compared for Brigatinib vs Crizotinib in NSCLC

The researchers found that the rate of progression-free survival was higher with brigatinib compared with crizotinib (estimated 12-month progression-free survival, 67% vs 43%; hazard ratio for disease progression or death, 0.49).